Process signatures in glatiramer acetate synthesis: structural and functional relationships

Area of Science:

• Immunology
• Pharmaceutical Sciences
• Polymer Chemistry

Background:

• Glatiramer Acetate (GA) is an immunomodulatory drug for multiple sclerosis with incompletely understood mechanisms.
• GA's complex polypeptide mixture and limited physicochemical data hinder a full understanding of its identity.
• Defining GA's unique attributes is crucial for elucidating its therapeutic actions.

Purpose of the Study:

• To investigate Glatiramer Acetate heterogeneities during manufacturing.
• To identify the impact of critical process parameters (CPPs) on GA's physicochemical characteristics.
• To correlate GA's structural attributes with its immunological and toxicological profiles.

Main Methods:

• Studied GA heterogeneities across its manufacturing process, termed 'process signatures'.
• Analyzed the influence of CPPs on amino acid precursor reactivity, polymerization kinetics, and peptide properties.
• Correlated specific GA heterogeneities with immunological and toxicological outcomes.

Main Results:

• Critical process parameters profoundly affect GA's reactivity, polymerization, solubility, hydrolysis susceptibility, and size-exclusion behavior.
• Distinct GA heterogeneities were linked to specific immunological responses mediated by unique epitopes.
• GA's physicochemical identity is influenced by intact peptide mixtures, not just degraded components.

Conclusions:

• Manufacturing process parameters critically shape Glatiramer Acetate's physicochemical identity and biological activity.
• GA contains unique active constituents (epitopes) responsible for its therapeutic effects.
• This study provides a novel framework for understanding GA structure-function relationships for consistent product manufacturing.